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Abstract: Problem statement: At present, the development of protective strategy against Alzheimer’s 
Disease (AD) is increasing its importance due to the high prevalence of AD, a limitation of therapeutic 
efficacy and its high impacts on economic and social aspects. The development of the preventive and 
therapeutic  strategy  to  protect  against  the  path  physiology  induced  by  free  radicals  in  AD  from 
antioxidant  has  gained  very  much  concentration.  Quercetin,  one  of  the  flavonoids  in  fruits  and 
vegetables, has a powerful antioxidant activity both in vitro and in vivo. However, poor absorption, 
rapid  metabolism  and  limited  ability  to  cross  the  blood-brain-barrier  are  obstacles  to  its  use  for 
treatment of AD. Liposome’s have been used as an effective delivery system to the brain. Advantages 
associated with the nasal administration over oral route include higher bioavailability due to no first 
pass hepatic metabolism and rapid absorption leading to shorter time to onset of effect. Based on all 
these  points,  the  possible  effects  of  quercetin  liposomes  via  nasal  route  on  improving  cognitive 
behavior  and  neurodegeneration  in  animal  model  of  Alzheimer’s  disease  were  investigated. 
Approach:  Male  Wistar  rats  were  pretreated  with  quercetin  liposome’s,  containing  0.5  mg  of 
quercetin in 20  L (dose = 20  g), via intranasal route once daily continually for 2  weeks before  and 
1 week after AF64A administration. Learning and memory was evaluated using the Morris water maze 
test at 7 days after the AF64A administration and then the rats were sacrificed for determining the 
density  of  neurons  and  cholinergic  neurons  in  hippocampus  using  histological  and 
immunohistochemical techniques. Results: Nasal administration of quercetin liposome’s significantly 
prevented changes of spatial memory of AF64A treated rats. The cognitive enhancement of quercetin 
liposome’s was found to be related to its ability to inhibit the degeneration of neurons and cholinergic 
neurons  in  hippocampus.  Conclusion:  Nasal  administration  of  quercetin  liposome’s  possessed 
cognitive  enhancer  and  neuroprotectant  in  animal  model  of  AD,  suggesting  a  potential  novel 
therapeutic strategy against AD of quercetin liposomes.  
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INTRODUCTION 
 
  Alzheimer’s  Disease  (AD)  is  a  progressive  and 
complex  neurodegenerative  disease,  characterized  by 
progressive  decline  in  memory,  language  and  other 
cognitive functions. It is associated with impairment of 
the basal forebrain cholinergic system, especially in the 
elderly (Auld et al., 2002). At present, the etiology of 
AD is remains a mystery, which makes the treatment of 
AD  a  challenge.  Based  on  the  results  of  extensive 
experimental  work,  free  radicals  appear  to  be  a  major 
culprit causing cellular damage. Several studies provide 
evidence  to  link  neuronal  damage  with  excessive 
generation of free radicals, which may be due to factors 
such as oxidative stress (Olanow, 1993), inflammation 
(Stuchbury  and  Munch,  2005),  abnormal  proteins 
(Mandelkow et al., 2007) or unknown factors. It has been 
observed that the use of antioxidants as well as dietary 
improvements with regard to the consumption of fruits 
and  vegetables  high  in  antioxidant  activity  and 
neuroprotective agents may decrease the risk of memory 
deficits of the AD type (Weinstock and Shoham, 2004). 
  Quercetin, a member of the flavonoids family, is 
one  of  the  most  prominent  dietary  antioxidants.  It  is Am. J. Agri. & Biol. Sci., 5 (3): 286-293, 2010 
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ubiquitously  present  in  foods  including  vegetables, 
fruit, tea and wine (Formica and Regelson, 1995), as 
well as countless food supplements and is claimed to 
exert beneficial health effects such as antivirus (Ohnishi 
and  Bannai,  1993),  certain  forms  of  cancer  (Lamson 
and  Brignall,  2000),  pulmonary  and  cardiovascular 
diseases  (Middleton  et  al.,  2000)  but  also  as 
neroprotection (Cho et al., 2006). The idea of applying 
quercetin as the agent to improve memory deficit and 
neuroprotectant  has  become  attractive.  In  order  to 
apply  quercetin  for  this  case,  it  is  necessary  to 
overcome the limitations of quercetin: Poor absorption 
and  very  low  distribution  to  the  brain  after  oral 
administration  (Boer  et  al.,  2005)  due  to  both  rapid 
metabolism (Manach et al., 1998) and difficulties in the 
penetration  through  the  Blood-Brain  Barrier  (BBB) 
(Youdim et al., 2004). An effective dose of quercetin to 
exert  certain  neurological  activities  could  be  relatively 
high because of first-pass metabolism (Bhattaram et al., 
2002).  
  Liposomes have long been used as a Drug Delivery 
System (DDS) to the brain, because the particles can 
entrap the compounds and prevent rapid elimination or 
degradation as well as promote penetration through the 
BBB which in turn decrease the effective dose (Sharma 
and  Sharma,  1997).  In  addition,  they  do  not  elicit 
negative biological responses that generally occur when 
a foreign  material is introduced in the system. These 
lipid  vesicles  are  non-toxic,  non-immunogenic,  no 
carcinogenic,  non-thrombogenic  and  biodegradable 
(Sinha et al., 2001). 
  Nasal  administration,  a  noninvasive  delivery 
system, could produce higher bioavailability than oral 
route due to the decrease hepatic metabolism, shorter 
distance to brain target and easy penetration through the 
brain (Wang et al., 2006; Illum, 2000).  
  Based  on  this  information,  we  hypothesized  that 
quercetin  liposomes  via  nasal  administration  could 
mitigate  the  memory  impairment  and 
neurodegeneration  in  animal  model  of  Alzheimer’s 
disease. 
 
MATERIALS AND METHODS 
 
  High-purity egg L-α-phosphatidylcholine, type XVI-
E  (EPC),  cholesterol  (chol),  quercetin  dihydrate  (98% 
HPLC purity) and Polyethylene Glycol 400 (PEG) were 
purchased  from  Sigma  (Barcelona,  Spain).  Other 
reagents used were analytical grade such as chloroform, 
ethanol  and  methanol  (HPLC  and  analytical  grade) 
from  BDH  Laboratory  Supplies  (Poole,  England), 
disodium  hydrogen  phosphate,  perchloric  acid  and 
ortho phosphoric acids (Merck, Darmstadt, Germany), 
sodium  dihydrogen  phosphate  (JT  Baker  Inc., 
Phillipsburg, New Jersey). All other chemicals were at 
least reagent grade and used as received. 
 
Preparation  of  quercetin  liposomes:  Quercetin 
dehydrate  (98%),  high-purity  egg  L-α-
phosphatidylcholine,  Type  XVI-E  (EPC)  and 
Cholesterol  (CHOL)  were  prepared  as  quercetin 
liposomes.  The  method  used  was  lipid  thin  film 
formation and extrusion (Guo et al., 2003; Liang et al., 
2005; Zu et al., 2006).  
 
Animals: Adult male Wistar rats (180±20 g, 8 weeks 
old)  were  obtained  from  National  Animal  Center, 
Salaya, Nakhon Pathomand they were housed in group 
of five per cage in standard metal cages at 22±2°C on 
12:12 h light-dark cycle. All animals were given access 
to  food  and  water  ad  libitum.  The  experiments  were 
performed to minimize animal suffering in accordance 
with  the  internationally  accepted  principles  for 
laboratory use and care of European Community (EEC 
directive of 1986; 86/609/EEC). 
  The experimental protocols were approved by the 
Institutional Animal Care and Use Committee. 
 
Experimental  protocol:  All  rats  were  randomly 
assigned to five groups of eight animals each: 
  
·  Free liposomes + ACSF: the rats in this group were 
administered  free  liposomes  via  nasal  route  then 
they  were  administered  artificial  cerebrospinal 
fluid  or  ACSF  bilaterally  via 
intracerebroventricular route  
·  PEG  +  ACSF:  the  rats  in  this  group  were 
administered  PEG  which  used  as  vehicle  of 
quercetin liposomes via nasal route and subjected 
to ACSF administration  
·  Free  liposomes  +  AF64A:  all  rats  were 
administered free liposomes via nasal route then, 
they  were  administered  AF64A  bilaterally  via 
intracerebroventricular route  
·  PEG  +  AF64A:  the  animals  were  administered 
PEG via nasal route then they were administered 
AF64A as mentioned in group 3  
·  QCL  +  AF64A:  the  rats  in  this  group  were 
administered quercetin liposomes via nasal route, 
then they were administered AF64A  
 
  All  animals  were  administered  freshly  prepared 
quercetin liposomes, containing 0.5 mg of quercetin in 
20  L (dose = 20  g), or liposomes without quercetin at 
the  same  volume  via  right  nasal  cavity  with  a 
micropipette at a period of 2 weeks before and 1 week Am. J. Agri. & Biol. Sci., 5 (3): 286-293, 2010 
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after AF64A or Artificial Cerebrospinal Fluid (ACSF) 
administration. The animals were determined the spatial 
memory 1 week after AF64A administration then they 
were sacrificed and determined the density of survival 
neurons and cholinergic neurons in various subregions 
of hippocampus. 
 
AF64A  administration:  AF64A  was  prepared  as 
described  previously  by  Hanin  (1996).  Briefly,  an 
aqueous  solution  of  acetylethylcholine  mustard  HCl 
(Sigma, St. Louis, MO) was adjusted to pH 11.3 with 
NaOH. After stirring for 30 min at room temperature, 
the pH was lowered to 7.4 with the gradual addition of 
HCl and stirred for 60 min. The amount of AF64A was 
then  adjusted  either  to  2  nmol/2  µL.  The  vehicle  of 
AF64A  was  distilled  water  prepared  in  the  same 
manner  as  the  AF64A  and  recognized  as  ACSF.  In 
order  to  administer  AF64A  bilaterally  via 
intracerebroventricular (i.c.v.) route, the animals were 
anesthetized  with  the  intraperitoneal  injection  of 
sodium pentobarbital at dose of 60 mg kg
-1 BW. Then, 
AF64A  (2  nmol/2  µl)  was  infused  bilaterally  via 
intracerebroventricular  (i.c.v.)  route  with  a  30-gauge 
needle inserted through a burr hole drilled into the skull 
into both the right and left lateral ventricles. Stereotaxic 
coordinates were (from the bregma): Posterior 0.8 mm, 
lateral ±1.5 mm and ventral (from dura) 3.6 mm. The 
rate of infusion was 1.0 µl min
-1 and the needle was left 
in  place  for  5  min  after  infusion  and  then  slowly 
withdrawn. 
  
Morris water maze test (behaviors evaluation): The 
water  maze  consisted  of  a  metal  pool  (170  cm  in 
diameter × 58 cm tall)  filled  with  tap  water  (25°C, 
40 cm deep) divided into four quadrants. In the center 
of  one  quadrant  was  a  removable  escape  platform 
below the water level and covered with a nontoxic milk 
powder. The pool was divided into four quadrants (NE, 
NW, SE and SW) by two imaginary lines crossing the 
center  of  the  pool.  For  each  animal,  the  location  of 
invisible  platform  was  placed  at  the  center  of  one 
quadrant and remained there throughout training. The 
rats must memorize the platform location in relation to 
various environmental cues because there was nothing 
directly shows the location of the escape platform in 
and outside the pool. Therefore, the placement of the 
water tank and platform were the same in all acquisition 
trials. Each rat was gently placed in the water facing the 
wall of the pool from one of the four starting points (N, 
E,  S,  or  W)  along  the  perimeter  of  the  pool  and  the 
animal was allowed to swim until it found and climbed 
onto the platform. During training session, the subject 
was gently placed on the platform by the experimenter 
when it could not reach the platform in 60 sec. In either 
case, the subject was left on the platform for 15 sec and 
removed from the pool. The time for animals to climb 
on the hidden platform was recorded as escape latency 
or acquisition time. In addition to the acquisition test, 
the determination of retention memory was carried out 
on the next day. According to this test, the platform was 
removed  and  the  animals  were  placed  into  the  water 
maze for 60 sec. The retention of memory or the time 
that  the  animal  spent  to  swim  around  the  previous 
location of platform before removing the platform on 
the test occurring in the next day was also recorded. It 
has been postulated that if the spatial memory of the rat 
for the trained platform location is accurate, the rat will 
swim  to  the  platform  location  and  search  around  the 
exact location. Therefore, the more accurate the spatial 
memory is, the greater the number of times rat swim 
across the trained platform. In each trial, the animal was 
quickly dried with towel before being returned to the 
cage. All test in Morris water maze tests were carried 
out within 30 min after the nasal administration of the 
substances.  
  Any enhancement of cognition would be reflected 
by  a  decrease  in  escape  latency  and  increase  in 
retention time. 
 
Histological  procedure:  Following  anesthesia  with 
sodium pentobarbital (60 mg kg
-1 BW), fixation of the 
brain  was  carried  out  by  transcardial  perfusion  with 
fixative solution containing 4% par formaldehyde  in 
0.1  M  phosphate  buffer  pH  7.3.  The  brains  were 
removed after perfusion and stored over a night in a 
fixative  solution  that  used  for  perfusion.  Then,  they 
were  infiltrated  with  30%  sucrose  solution  for 
approximately 4°C. The specimens were frozen rapidly 
and 30  M thick sections were cut on cryostat. They 
were rinsed in the phosphate buffer and picked up on 
slides coated with 0.01% of aqueous solution of a high 
molecular weight poly L-lysine. 
 
Nissl staining: The duplicate coronal sections of brains 
were  stained  with  0.75%  cresyl  violet,  dehydrated 
through graded alcohols (70, 95, 100% 2×), placed in 
xylene and coverslipped using DPX mountant. 
  
Choline  acetyltransferase  and 
immunohistochemistry: A series of section containing 
hippocampus from each groups were reacted in parallel 
experiments  using  a  mouse  monoclonal  antibody 
detected  against  Choline  Acetyltransferase  (ChAT) 
(Chemicon  Internation,  Inc.,  CA,  USA)  and  a 
modification  of  a  previously  described  protocol 
employing the DAKO Strept ABC Complex/HRP duet Am. J. Agri. & Biol. Sci., 5 (3): 286-293, 2010 
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kit. In brief, the sections were eliminated endogenous 
peroxidase activity by 0.5%H2O2 in methanol. Sections 
were washed in running tap water and distilled water 
for 1 min each, then rinsed in KPBS and KPBS-BT for 
5  min  per  each  process.  Excess  was  removed,  then 
incubated for 30 min in a blocking solution composed 
of 5% normal horse serum in KPBS-BT. The sections 
were then incubated in mouse primary antibody against 
ChAT diluted 1 : 100 in KPBS-BT at room temperature 
for 2 h and then incubated at 4 C for 48 h. The tissue 
was rinsed in KPBS-BT (two washes´7 min), incubated 
for  4  h  in  biotinylated  goat  antimouse  IgG  antibody, 
rinsed  in  KPBS-BT  (two  washes´7  min)  and  then 
incubated  in  Strep  ABCComplex/HRP  for  4  h.  In 
preparation for visualization step, sections were rinsed 
in KPBS-BT (1 min) and KPBS (two washes´10 min). 
ChAT immunoreactivity was visualized using 0.025% 
3,  3’  Diaminobenzidine  (DAB,  Sigma)  and  0.01% 
H
2O
2.  Finally,  sections  were  rinsed  in  running  tap 
water, air dried and cover-slipped using permount. 
 
Statistical  analysis:  Data  are  presented  as  mean  ± 
standard error of mean (± SEM). One-way Analysis Of 
Variance  (ANOVA),  followed  by  Duncan’s  post  hoc 
test. A probability level less than 0.05 was accepted as 
significance.  
 
RESULTS 
 
Effect of quercetin liposomes on spatial memory in 
AF64A treated rats: Figure 1 and 2 shows that ACSF 
produced no significant changes on both escape latency 
and  retention  time  in  Morris  water  maze  test. 
Intracerebroventricular  administration  of  AF64A 
significantly  increased  escape  latency  but  decreased 
retention  time  (p-value<0.001  all;  compared  to  both 
liposomes + ACSF and PEG + ACSF). This indicated 
the memory impairment induced by AF64A. Rats that 
received AF64A and nasal administration of quercetin 
liposomes  showed  significantly  decreased  acquisition 
and  increased  retention  time  (p-value<0.001  all; 
compared to liposomes + ACSF and PEG + AF64A). 
Therefore, our data indicated that quercetin liposomes 
via nasal administration improved the memory deficit 
induced by AF64A. 
 
Neuroprotective  effect  of  quercetin  liposomes  in 
AF64A treated rats: The effect of quercetin liposomes 
on  the  neurons  density  in  various  subregions  of 
hippocampus was shown in Fig. 3. Both liposomes and 
PEG had been previously demonstrated to produce no 
harmful effect on neuron density. The administration of 
AF64A  in  either  liposomes  or  PEG  treated  groups 
significantly  decreased  the  neuron  density  in  CA1, 
CA2,  CA3  and  dentate  gyrus  (p-value<0.001  all; 
compared  to  both  liposomes  +  ACSF  and  PEG  + 
ACSF).  Surprisingly,  quercetin  liposomes 
administration     could     reverse     these     changes 
(p-value0.001 all; compared to liposomes + ACSF and 
PEG + AF64A). 
  
 
 
Fig. 1:  Effect  nasal  administration  of  quercetin 
liposomes  on  the  acquisition  time  of  spatial 
learning in the Morris water maze test (N = 8). 
Results were expressed as mean ± SEM; 
*: P-
value<0.001 compared with liposomes + ACSF 
treated group; 
#: p-value<0.001 compared with 
PEG + ACSF treated group; 
a: p-value<0.001 
compared  with  liposomes  +  AF64A  treated 
group; 
b: p-value<0.001 compared with PEG + 
AF64A treated group 
 
 
 
Fig. 2:  Effect  nasal  administration  of  quercetin 
liposomes  on  the  retention  time  of  spatial 
learning in the Morris water maze test (N = 8). 
Results  are  expressed  as  mean  ±  SEM; 
*:  p-
value<0.001 compared with liposomes + ACSF 
treated  grou; 
#:
  p-value<0.001  compared  with 
PEG  +  ACSF  treated  group; 
a:
  p-value<0.001 
compared  with  liposomes  +  AF64A  treated 
group; 
b: p-value<0.001 compared with PEG + 
AF64A treated group Am. J. Agri. & Biol. Sci., 5 (3): 286-293, 2010 
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Fig. 3:  Effect  nasal  administration  of  quercetin 
liposomes  on  the  density  of  neurons  in 
hippocampus. (N = 8)  Results were expressed 
as mean ± SEM; 
*: p-value<0.001 compared 
with   liposomes  +  ACSF    treated    group; 
#:
 p-value<0.001 compared with PEG + ACSF 
treated group; 
a:
 p-value<0.001  compared with 
liposomes     +       AF64A     treated      group; 
b:
 p-value<0.001 compared with PEG + AF64A 
treated group 
 
 
 
Fig. 4:  Effect  nasal  administration  of  quercetin 
liposomes  on  the  density  of  cholinergic 
neurons in hippocampus. Results are expressed 
as  mean  ±  SEM; 
*:
  p-value<0.001  compared 
with   liposomes   +    ACSF    treated    group; 
#: p-value<0.001 compared with PEG + ACSF 
treated group; 
a: p-value<0.001 compared with 
liposomes     +       AF64A       treated     group; 
b: p-value<0.001 compared with PEG + AF64A 
treated group 
 
 
  We also determined the effect of all interventions 
mentioned earlier on the density of cholinergic neurons 
in hippocampus, the area playing an important role on 
spatial  memory.  Data  were  shown  in  Fig.  4.  AF64A 
produced  significant  reduction  in  cholinergic  neurons 
densities  in  all  areas  of  hippocampus  (p-value<0.001 
all; compared to both liposomes + ACSF and PEG + 
ACSF) whereas quercetin liposomes could significantly 
attenuate  the  decrease  cholinergic  neurons  densities 
induced by AF64A in all subregions of hippocampus 
(p-value<0.001  all;  compared  to  liposomes  +  AF64A 
and PEG + AF64A).  
  
DISCUSSION 
 
  The  current  study  demonstrates  that  nasal 
administration  of  quercetin  liposomes  could  mitigate 
the  memory  impairment  and  the  degeneration  of 
neurons  and  cholinergic  neurons  in  hippocampus  in 
animal  model  of  Alzheimer’s  disease  induced  by 
AF64A. 
  Various  degrees  of  cognitive  impairment  were 
reported to be associated with cholinergic neuronal loss 
and  dysfunction  especially  in  AD  (Bondy,  1995). 
Recently, a pile of evidence suggested that the prime 
candidate  responsible  for  producing  the  neuronal 
changes mediating these cognitive deficits appeared to 
be free radicals and oxidative stress generated (Mattson, 
2004;  Cantuti  et  al.,  2000).  Therefore,  many  studies 
focused  on  the  beneficial  effects  of  supplement 
possessing a capability to improve cholinergic function 
and antioxidant activity  were also considered to be a 
potential  candidate  for  neuroprotective  agent  against 
AD. 
  Quercetin,  a  main  flavonoid  found  in  fruits, 
vegetables  and  beverages,  was  reported  to  possess 
antioxidant  and    cognition    (Boots    et    al.,    2008; 
Reiter  et  al.,  2009).  Previous  studies  confirm  that 
quercetin  supplementation  improve  memory  deficit 
condition induced by reserpine in mice (Naumenko and 
Kulikov, 2006). However, it was reported that quercetin 
was easily metabolized after absorption (Manach et al., 
2004). Our study found it worthwhile to use the vesicle 
mediated  carrier  system  particularly  liposomes  to 
encapsulated  the  quercetin  against  Alzheimer’s 
condition induced by AF64A.  
  Intracerebroventricular  injection  by  AF64A  has 
been  described  as  an  appropriate  the  substance  to 
destroy  the  cholinergic  system  and  induce  memory 
deficit (Hanin, 1996; McDonald and Overmier, 1998). 
In the present study, the results show that both in the 
AF64A  +  free  liposomes  and  AF64A  +  PEG  treated 
groups, caused a persistent memory deficit as evidenced 
by  a  significant  induction  in  acquisition  time  and 
reduction in retention time in Morris water maze. This 
deficit in memory was reversed by quercetin liposomes 
via nasal route. Pretreatment with nasal administration 
of  quercetin  liposomes  improved  spatial  memory  as 
evidenced  by  improved  performance  in  Morris  water 
maze test.  Am. J. Agri. & Biol. Sci., 5 (3): 286-293, 2010 
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  The evidence stems  from data of several authors 
demonstrated  that  memory  impairment  especially  the 
spatial memory or hippocampal dependent memory was 
tightly  associated  with  the  neurodegeneration  in 
hippocampus, which in turn depended on the density of 
neurons  particularly  cholinergic  neurons  (Katzman, 
1986; Mori et al., 1997). Our results demonstrated that 
in  the  AF64A  +  free  liposomes  and  AF64A  +  PEG 
treated  groups,  there  were  the  reduction  of  survival 
neurons  and  cholinergic  neurons  in  all  areas  of 
hippocampus.  Interestingly,  in  AF64A  with  nasal 
administration of quercetin liposomes treated group, the 
rats  showed  significantly  improved  the  density  of 
survival neurons and cholinergic neurons in all areas of 
hippocampus as compared to the AF64A + PEG or free 
liposomes treated rats. Moreover, it was notable that the 
density of cholinergic neurons of quercetin liposomes 
plus  AF64A  treated  group  were  higher  than  those 
obtained from the liposomes + ACSF and PEG + ACSF 
treated  group.  This  suggests  that  quercetin  liposomes 
not  only  the  neuroprotective  effect  but  also  the 
neurotrophic  effect  to  stimulate  the  neurogenesis  in 
hippocampus.  Previous  study  demonstrated  that  the 
neurogenesis  could  occur  throughout  adulthood 
especially in hippocampus and subventricular zone of 
lateral  ventricle  (Hagg,  2005).  Numerous  factors  had 
been reported to be regulators of the adult neurogenesis. 
To  clarify  this  issue,  further  researches  are  still 
essential.  
  Our results demonstrated that nasal administration 
of  quercetin  encapsulated  liposomes  was  a  potential 
novel  strategy  to  protect  against  neurodegeneration 
such as AD. It was noticeable that the dose of quercetin 
required via nasal administration was very much low 
dose and rapid onset of cognitive enhancing effect. In 
this respect, quercetin could be delivered to the brain 
even though it was administered in nondissolved form 
in a liquid that was not a good candidate for delivery of 
this hydrophobic compound (Cho et al., 2006). Some of 
the  suspended  particles  of  quercetin  might  not  be 
absorbed after all. Our present study suggests that the 
enhanced delivery of quercetin in the form of liposomes 
to the brain could effectively reduce the dose,  which 
would  also  reduce  the  potential  of  toxicity  of  the 
substance  (Metodiewa  et  al.,  1999)  and  increase 
bioavailability  (Jamal  et  al.,  2000).  Moreover,  it  was 
also  provided  numerous  benefits  especially  the  direct 
nose-to-brain  delivery,  bypassing  the  blood  brain 
barrier  (Wu  et  al.,  2008)  and  avoid  the  first  pass 
metabolism  (Graf  et  al.,  2006).  However,  the  main 
proposed  pathway  of  quercetin  delivery  via  nasal 
administration was different. It was likely to permeate 
through  the  subarachnoid space through  the olfactory 
epithelium  and  found  in  the  CSF  later,  because  the 
liposomes  behaved  as  semilipophilic  particles. 
Therefore,  quercetin  liposomes  could  rapidly  absorb 
into the CSF. Investigation of quercetin absorption and 
distribution after administered via nasal route would be 
of value for future studies.  
 
CONCLUSION 
 
  Nasal  administration  of  quercetin  liposomes 
improves  both  memory  impairment  and 
neurodegeneration  in  cognitive  deficit  condition 
induced  by  AF64A,  suggesting  a  potential  valuable 
candidate  for  cognitive  enhancer  and  neuroprotective 
agent in AD. 
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